Navigation Links
Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
Date:1/25/2013

DEERFIELD, Ill. and OSAKA, Japan, Jan. 25, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

"Takeda is pleased with the FDA approval of NESINA, OSENI and KAZANO for the treatment of type 2 diabetes, a therapeutic category in which we have more than twenty years of clinical and patient experience," said Douglas Cole , president, Takeda Pharmaceuticals U.S.A., Inc. "Millions of people are affected by diabetes and, as a leader in the diabetes arena, Takeda is dedicated to working to advance patient care and helping to meet the needs of this growing patient population."

NESINA is a dipeptidyl peptidase-4 inhibitor (DPP-4i) that is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). OSENI, which combines alogliptin with pioglitazone, is the first product in the U.S. to include both a DPP-4i and a thiazolidinedione (TZD) in a single tablet. KAZANO combines alogliptin with metformin HCl, a widely used anti-diabetes medication, in a single tablet.

The most common adverse events (greater than or equal to 4%) reported with NESINA include nasopharyngitis, headache and upper respiratory tract infection. With regard to OSENI, common adverse events (greater than or equal to 4%) reported include nasopharyngitis, back pain and upper respiratory tract infection. Common adverse events (greater than or equal to 4%) re
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
2. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
3. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
4. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
5. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
6. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
7. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
8. Zimmer Receives FDA Clearance for Revolutionary New Surgical Guidance Technology
9. American Capital Receives $60 Million From The Sale Of Lifoam Holdings And Generates An 11% Return On Its Investment
10. PrimeMail, Prime Therapeutics mail-service pharmacy, receives URAC Reaccreditation
11. Brolex C SAFE cesarean section safety device receives top scores, rated a MUST HAVE medical device for performing c/sections.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... CHICAGO and SOUTH SAN ... -- The Pulmonary Fibrosis Foundation (PFF) and ... announced that the organizations are partnering on a ... diagnostic experiences with interstitial lung diseases (ILDs), including ... Patient Journey (INTENSITY) survey will assess the steps ...
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ ... the "Company"), a biopharmaceutical company focused on the development ... it will release its year-end financial results for the ... 4, 2015. DelMar,s management team will ... for investors, analysts and other interested parties on Friday, ...
(Date:8/27/2015)... August 27, 2015 The global ... reach USD 3.96 billion by 2022, according to a ... of chronic venous disorders such as deep vein thrombosis, ... serve as the key driver.      (Logo: ... injuries are also expected to boost market growth over ...
Breaking Medicine Technology:Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 2Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 5
... ANGELES, April 17, 2007 /PRNewswire/ -- Researchers from ... presented,strong evidence today that an antibiotic typically prescribed ... types of cancers. , Q. Ping Dou, Ph.D., ... lab announced the findings of their study showing,that ...
... LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - ZIOPHARM ... of preclinical,data strongly supportive of the development ... demonstrates very high,bioavailability when administered orally; in ... well suited to oral,administration. These data were ...
Cached Medicine Technology:Alzheimer's Drug Shows Promise in Fighting Cancer 2ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR 2ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR 3
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... array of instruments available for quantitative PCR (qPCR) in the last ... higher throughput and reduced operating costs. On the flipside, where do lab managers, ...
(Date:8/27/2015)... PA (PRWEB) , ... August 27, 2015 , ... ... Health Network , is one of just 20 adult-only medical centers in the ... for people with failing hearts and lungs. The Extracorporeal Life Support Organization ...
(Date:8/27/2015)... ... 27, 2015 , ... The Naderi Center is proud to announce that its ... procedure to improve submental fat. The first and only Food and Drug Administration ... Dr. Kulak is the only Board Certified surgeon in the D.C., Maryland, Virginia area ...
(Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are becoming pet-friendly, ... Amica Insurance is sharing some tips to help your whole family travel safely and ... travel with pets each year. Amica is sharing the following tips from the American ...
(Date:8/27/2015)... , ... August 27, 2015 ... ... Swan Analysis signed a partnership agreement for quality market research promotion on ... elaborated by Black Swan Analysis. , Commenting on the partnership agreement, Natalie ...
Breaking Medicine News(10 mins):Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 2Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... CEL-SCI Corporation (NYSE AMEX: CVM ) announced today financial results ... results: , , ... of 41% compared to a net loss of $3,210,294 during the same quarter ... loss per common share for the quarter ended March 31, 2009 was $0.02 ...
... 15 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: ... quarter ended March 31, 2009. Amounts, unless specified ... accordance with Canadian Generally Accepted Accounting Principles (Canadian ... 2009, the exchange rate was CAD$1.00=US$0.7928.Results of OperationsWe ...
... PARIS, FRANCE The International Union for Health ... Health Education (SOPHE) are pleased to release today special, ... and quality assurance systems of global capacity in health ... Education & Behavior (Vol. 36, No. 3, June ...
... Help Employers and Business Owners Plan for Pandemic ImpactPLYMOUTH ... hosting two free webinars on May 19, 2009 to ... Following the webinar Health Advocate will release a special ... summarizing steps for employers to take.Two experts - ...
... May 15 Within weeks, the University of ... campus that will provide a springboard for new discoveries, ... wise investment for U-M,s future.U-M,s purchase of the former ... North Campus will be completed on June 16, said ...
... of Medicine (BUSM) have found a high frequency ... the largest neonatal intensive care units (NICUs) in ... methods could reduce the vast number of hospital ... in the journal Infection Control and Hospital ...
Cached Medicine News:Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 2Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 3Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 4Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 5Health News:Cardiome Reports First Quarter Results 2Health News:Cardiome Reports First Quarter Results 3Health News:Cardiome Reports First Quarter Results 4Health News:Special journal issues released on global health promotion and health education 2Health News:Experts to Discuss Worksite Preparedness Measures During May 19th Pandemic Flu Webinars 2Health News:U-M Purchase of Former Pfizer Facility Nears Completion, Paving the Way For Research Expansion and Job Creation 2Health News:BUSM researchers find gram-negative rods in two Philippine neonatal intensive care units 2
Express Elyte Systems....
... 1650 has minimal requirements for ... 2 L/test), reagent consumption (as ... water consumption (25 L/hour) - ... universal rack handler facilitates continuous ...
Iron Total (TIBC) (Iron Buffer + Iron Color=Std.). An Automated analyzer test kits....
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
Medicine Products: